| 10.52 0.465 (4.62%) | 08-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.79 | 1-year : | 17.56 |
| Resists | First : | 12.66 | Second : | 15.03 |
| Pivot price | 11.07  |
|||
| Supports | First : | 8.82 | Second : | 7.34 |
| MAs | MA(5) : | 9.9  |
MA(20) : | 11.71 |
| MA(100) : | 11.12 |
MA(250) : | 9.96 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 27.1 |
D(3) : | 20.6 |
| RSI | RSI(14): 40.7 |
|||
| 52-week | High : | 15.03 | Low : | 7.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZVRA ] has closed above bottom band by 40.0%. Bollinger Bands are 118.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.54 - 10.58 | 10.58 - 10.63 |
| Low: | 9.99 - 10.03 | 10.03 - 10.08 |
| Close: | 10.44 - 10.51 | 10.51 - 10.59 |
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
Tue, 04 Aug 2026
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference - GlobeNewswire
Tue, 04 Aug 2026
Zevra executives set to present at Boston growth conference - Stock Titan
Mon, 03 Aug 2026
Zevra Therapeutics Announces Publication of 4-Year Real-World Data on MIPLYFFA in Niemann-Pick Disease Type C - Quiver Quantitative
Fri, 31 Jul 2026
Zevra Therapeutics, Inc. - Common Stock (NQ: ZVRA - FinancialContent
Thu, 30 Jul 2026
Zevra Therapeutics (ZVRA) Stock Forum and Discussion - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 1.2 (%) |
| Held by Institutions | 73.4 (%) |
| Shares Short | 7,800 (K) |
| Shares Short P.Month | 6,520 (K) |
| EPS | 2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.48 |
| Profit Margin | 101.5 % |
| Operating Margin | 24.3 % |
| Return on Assets (ttm) | 2.7 % |
| Return on Equity (ttm) | 100.6 % |
| Qtrly Rev. Growth | 77.5 % |
| Gross Profit (p.s.) | 1.78 |
| Sales Per Share | 2.06 |
| EBITDA (p.s.) | 0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 13 (M) |
| Levered Free Cash Flow | 26 (M) |
| PE Ratio | 5.23 |
| PEG Ratio | 10.6 |
| Price to Book value | 3.02 |
| Price to Sales | 5.08 |
| Price to Cash Flow | 48.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|